Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKanabo Grp Plc Regulatory News (KNB)

  • This share is currently suspended. It was suspended at a price of 0.225

Share Price Information for Kanabo Grp Plc (KNB)

Share Price is delayed by 15 minutes
Get Live Data
0.225    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £1.42m
KNB Live PriceLast checked at - London Stock Exchange

Intraday Kanabo Grp Plc Share Chart

Grant of Options

23 Jun 2023 07:00

RNS Number : 6602D
Kanabo Group PLC
23 June 2023
 

23 June 2023

Kanabo Group Plc

("Kanabo" or the "Company")

 

Grant of Options

 

Kanabo Group Plc (LSE:KNB), the patient focused healthcare technology and medicinal cannabis company, announces that on 19 June 2023 it granted options over a total of 25,050,000 ordinary shares in the Company ("Shares") to certain employees, pursuant to their terms of employment (the "Awards").

 

The Awards were granted were granted to certain persons discharging managerial responsibilities ("PDMR") and other employees, and are summarised below:

 

Name

No. of Options

Vested options as of today

Option Exercise Price

Vesting Period for non-vested options

David Tsur

Deputy Chair

2,000,000

-

2.88p

The options shall vest and become exercisable in twelve equal portions which shall vest over a 3-year period from the Vesting Start Date.

Ian Mattioli

Chair

3,000,000

-

2.88p

The options shall vest and become exercisable in four equal portions which shall vest over a 2-year period from the Vesting Start Date

Sharon Malka

Non-Executive Director

 

2,025000

-

2.88p

The options shall vest and become exercisable in four equal portions which shall vest over a 2-year period from the Vesting Start Date.

Assaf Vardimon

CFO

2,500,000

-

2.88p

The options shall vest and become exercisable in twelve equal portions which shall vest over a 3-year period from the Vesting Start Date.

Suleman Sacranie

CPO/CTO *

11,000,000

5,500,004

2.88p

The options shall vest and become exercisable in twelve equal portions which shall vest over a 3-year period from the Vesting Start Date.

Other Employees

2,500,000

-

2.88p

The options shall vest over a 3-year period. 33% vest at the end of the 12-month period following the Vesting Start Date. The remaining options vest over 8 equal 3-month periods thereafter.

Other Employees

2,025,000

-

2.88p

The options shall vest and become exercisable in twelve equal portions which shall vest over a 3-year period from the Vesting Start Date.

 

* Mr. Sacranie has agreed to surrender 5,829,400 Options granted on 31 August 2022 which carry exercise price of 6.5p and 8p.

 

 

 For further information, please visit http://www.kanabogroup.com/ or contact the following:

 

Enquiries:

 

Kanabo Group plc

Avihu Tamir, Chief Executive Officer

Assaf Vardimon, Chief Financial OfficerIan Mattioli, Non-Executive Chair of the Board

 

via Vigo Consulting

+44 (0)20 7390 0230

Peterhouse Capital Ltd (Financial Adviser and Broker)

Eran Zucker/ Lucy Williams / Charles Goodfellow

 

+44 (0)20 7469 0930

Vigo Consulting (Financial Public Relations/Investor Relations)

Jeremy Garcia / Fiona Hetherington / Verity Snow

kanabo@vigoconsulting.com

 +44 (0)20 7390 0230

 

 

 

 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.

 

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.

 

Visit www.kanabogroup.com for more information.

 

 

 

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

David Tsur

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

2.88p

2,000,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

19.6.2023

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Ian Mattioli

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

2.88p

3,000,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

19.6.2023

f)

 

Place of the transaction

 

 

London Stock Exchange

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Sharon Malka

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-Executive Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

2.88p

2,025,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

19.6.2023

f)

 

Place of the transaction

 

 

London Stock Exchange

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Assaf Vardimon

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

CFO

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

2.88p

2,500,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

19.6.2023

f)

 

Place of the transaction

 

 

London Stock Exchange

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Suleman Sacranie 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

CPO/CTO

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Kanabo Group Plc

b)

 

LEI

 

 

213800XPJFSNWJIYKN52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares

Identification code

GB00BYQCS703

b)

 

Nature of the transaction

 

 

Share Options

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

2.88p

11,000,000

d)

 

Aggregated information

- Aggregated volume

N/A

- Price

N/A

e)

 

Date of the transaction

 

 

19.6.2023

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCNKBBPFBKDFAB
Date   Source Headline
11th Dec 202511:30 amRNSDisposal of Subsidiary: The GP Service Limited
28th Nov 20254:02 pmRNSAppointment of Joint Administrators
1st May 20257:30 amRNSSuspension - Kanabo Group plc
30th Apr 20252:47 pmRNSTemporary suspension of listing
4th Apr 20254:20 pmRNSBusiness Update
24th Mar 202511:02 amRNSResignation of Director
4th Mar 20257:00 amRNSRevenue Growth, Trading and Operational Update
6th Jan 20257:00 amRNSDirectorate Change
31st Oct 20249:48 amRNSCorrection Director/PDMR Shareholding
29th Oct 202411:39 amRNSDirector/PDMR Shareholding
30th Sep 20242:50 pmRNSHalf-year Report
28th Aug 20242:31 pmRNSDirector/PDMR Shareholding
27th Jun 20244:49 pmRNSResult of AGM
4th Jun 20247:00 amRNSExpansion:14 New Clinics Partnership with Treat-It
31st May 202410:30 amRNSNotice of AGM
30th Apr 20242:15 pmRNSAnnual Financial Report
28th Mar 20247:00 amRNSExpansion of Treat It to Mental Health Treatments
27th Mar 20245:11 pmRNSHolding(s) in Company
25th Mar 20247:00 amRNSGermany Medical Cannabis Legislation Reform
18th Mar 20249:14 amRNSAgritec Update
15th Jan 20247:00 amRNSPartnership to launch a Walk-In Pain Clinic
14th Nov 20237:00 amRNSContract Extension With Major UK Retailer
2nd Nov 20237:00 amRNSPartnership with BRITISH CANNABISâ„¢
29th Sep 20237:00 amRNSHalf-Year Results
31st Aug 202311:13 amRNSTotal Voting Rights
11th Aug 202311:36 amRNSIssuance of New Ordinary Shares and TVR
26th Jul 20232:00 pmRNSAdmission and Total Voting Rights
24th Jul 20234:10 pmRNSIssuance of New Ordinary Shares and TVR
17th Jul 20237:00 amRNSSuccess for Kanabo Agritec with Contract Award
10th Jul 202311:19 amRNSIssue of New Ordinary Shares and TVR
30th Jun 20232:34 pmRNSResult of AGM
28th Jun 20237:00 amRNSIssue of New Ordinary Shares and TVR
23rd Jun 20237:00 amRNSGrant of Options
13th Jun 20232:39 pmRNSPublication of a Prospectus
8th Jun 20235:19 pmRNSNotice of Annual General Meeting
31st May 202311:30 amRNSTotal Voting Rights
26th May 202310:30 amRNSTotal Voting Rights
23rd May 202311:00 amRNSIssuance of New Ordinary Shares
16th May 20233:00 pmRNSUpdate: Amendments to Acquisition Agreement
16th May 20237:00 amRNSAmendments to Acquisition Agreement
15th May 20237:00 amRNSTotal Voting Rights
12th May 20237:00 amRNSTotal Voting Rights
10th May 20232:52 pmRNSResult of Broker Option
9th May 20237:00 amRNSAppointment of Ian Mattioli as Non-Executive Chair
9th May 20237:00 amRNSFundraise of £2.54 million and Broker Option
4th May 20234:45 pmRNSBoard Change
2nd May 20237:00 amRNSFull Year Results 2022
31st Mar 20232:40 pmRNSDirectorate Change
13th Mar 20237:00 amRNSTreat It Launch: Online Medicinal Cannabis Clinic
7th Mar 202312:15 pmRNSAppointment of Auditor

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.